Efficacy and Safety of Dose-Escalated Alectinib in Patients With Metastatic ALK-Positive NSCLC and Central Nervous System Relapse on Standard-Dose Alectinib

Introduction: Central nervous system (CNS) metastases remain a common challenge in patients with ALK-positive NSCLC. We previously reported reinduction of CNS responses using dose-intensified alectinib in two patients with CNS progression on standard-dose alectinib. Nevertheless, this strategy has n...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Justin M. Cheung, MD, Jiyoon Kang, DO, Beow Y. Yeap, ScD, Jennifer L. Peterson, BS, Andrew Do, BS, Justin F. Gainor, MD, Subba R. Digumarthy, MD, Jessica J. Lin, MD
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Elsevier 2024-03-01
Sarja:	JTO Clinical and Research Reports
Aiheet:	Alectinib CNS Brain metastases ALK NSCLC
Linkit:	http://www.sciencedirect.com/science/article/pii/S2666364324000158
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!